|
1
|
Lenz M, Kaun C, Krychtiuk KA, Haider P, Brekalo M, Maier N, Goederle L, Binder CJ, Huber K, Hengstenberg C, Wojta J, Hohensinner PJ, Speidl WS. Effects of Nicorandil on Inflammation, Apoptosis and Atherosclerotic Plaque Progression. Biomedicines 2021; 9:biomedicines9020120. [PMID: 33513743 PMCID: PMC7912627 DOI: 10.3390/biomedicines9020120] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 01/15/2021] [Accepted: 01/20/2021] [Indexed: 02/06/2023] Open
Abstract
Nicorandil, a balanced vasodilator, is used in the second-line therapy of angina pectoris. In this study, we aimed to illuminate the effects of nicorandil on inflammation, apoptosis, and atherosclerotic plaque progression. Twenty-five LDL-R -/- mice were fed a high-fat diet for 14 weeks. After 6 weeks mice were randomly allocated to treatment with nicorandil (10 mg/kg/day) or tap water. Nicorandil treatment led to a more stable plaque phenotype, displaying an increased thickness of the fibrous cap (p = 0.014), a significant reduction in cholesterol clefts (p = 0.045), and enhanced smooth muscle cell content (p = 0.009). In endothelial cells nicorandil did not reduce the induction of adhesion molecules or proinflammatory cytokines. In H2O2 challenged endothelial cells, pretreatment with nicorandil significantly reduced the percentage of late apoptotic/necrotic cells (p = 0.016) and the ratio of apoptotic to living cells (p = 0.036). Atherosclerotic lesions of animals treated with nicorandil exhibited a significantly decreased content of cleaved caspase-3 (p = 0.034), lower numbers of apoptotic nuclei (p = 0.040), and reduced 8-oxogunanine staining (p = 0.039), demonstrating a stabilizing effect of nicorandil in established atherosclerotic lesions. We suggest that nicorandil has a positive effect on atherosclerotic plaque stabilization by reducing apoptosis.
Collapse
Affiliation(s)
- Max Lenz
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
- Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria
| | - Christoph Kaun
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
| | - Konstantin A. Krychtiuk
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
- Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria
| | - Patrick Haider
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
| | - Mira Brekalo
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
| | - Nadine Maier
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
| | - Laura Goederle
- Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; (L.G.); (C.J.B.)
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Christoph J. Binder
- Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; (L.G.); (C.J.B.)
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
| | - Kurt Huber
- 3rd Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital and Sigmund Freud University, 1160 Vienna, Austria;
| | - Christian Hengstenberg
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
| | - Johann Wojta
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
- Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria
- Core Facility Imaging, Medical University of Vienna, 1090 Vienna, Austria
| | - Philipp J. Hohensinner
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
- Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria
- Correspondence: ; Tel.: +43-1-40400-73515
| | - Walter S. Speidl
- Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; (M.L.); (C.K.); (K.A.K.); (P.H.); (M.B.); (N.M.); (C.H.); (J.W.); (W.S.S.)
| |
Collapse
|
|
2
|
Younis T, Khan MR, Sajid M, Majid M, Zahra Z, Shah NA. Fraxinus xanthoxyloides leaves reduced the level of inflammatory mediators during in vitro and in vivo studies. Altern Ther Health Med 2016; 16:230. [PMID: 27430329 PMCID: PMC4949749 DOI: 10.1186/s12906-016-1189-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 07/01/2016] [Indexed: 12/22/2022]
Abstract
Background Different parts of Fraxinus xanthoxyloides Wall. (Oleaceae) are used traditionally in the treatment of internal wounds, bone fracture, pain, jaundice, malaria and in pneumonia. These ailments involve protective and essential mechanisms of the organism in response to infection, injury and trauma. However, prolonged inflammation may lead to inflammatory disorders. The present investigation was carried to evaluate the crude methanol extract of F. xanthoxyloides leaves and its fractions for their anti-inflammatory and analgesic effects. Methods Methanol extract of F. xanthoxyloides leaves was fractionated through liquid-liquid partition on escalating polarity of solvents. Acetic acid and thermal responses were used to evaluate the analgesic effects of extract/fractions in rat. Anti-inflammatory effects were monitored through in vitro; TNF-α activated NFkB in 293/NFkB-Luc HEK cells and LPS-activated nitric oxide (NO) assay in RAW 264.7 cells. For in vivo studies carrageenan induced paw edema model was used in rat. Both in vitro and in vivo studies have indicated that chloroform fraction exhibited superior anti-inflammatory effects to other extract/fractions and therefore, was used in air pouch model in rat to estimate the inhibition in leukocyte migration and synthesis of inflammatory mediators. In addition, phytochemical investigation of crude extract was carried out by GC-MS analysis. Results GC-MS studies of crude extract revealed the presence of various classes of which terpenoids (26.61 %), lactam (16.47 %), esters (15.81 %), phenols (8.37 %), and steroid (6.91 %) constituted the major categories. Among the extracts chloroform fraction (200 mg/kg bw) significantly (P <0.001) increased the percent latency time (76.13 ± 4.49 %) in hot plate test after 120 min and decreased (P <0.001) the count of writhes (77.23 ± 5.64 %) as compared to other extracts. The in vitro studies indicated that chloroform fraction at 15 μg/ml more effectively inhibited the TNF-α induced synthesis of NFkB (85.0 ± 8.12 %, IC50 = 5.98 μg/ml) and LPS-instigated nitric oxide (78.23 ± 2.39 %, IC50 = 6.59 μg/ml) synthesis. Although all the extract/fractions showed a dose dependent increase in inhibition of edema formation however, chloroform fraction (4th h = 77.64 ± 3.04 %) at 200 mg/kg bw exhibited relatively higher (P <0.001) anti-inflammatory activity in carrageenan-induced paw edema in rat. Moreover, chloroform fraction had the ability to decrease (P <0.001) the influx of leukocytes and the concentration of inflammatory mediators; TNF-α, NO, IL-6 and PGE2 in air pouch exudate. Conclusion The study demonstrates the therapeutic potential of F. xanthoxyloides leaves against the inflammatory disorders suggesting the presence of active constituents in chloroform fraction.
Collapse
|